Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 2,400 Shares

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 2,400 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $5.00, for a total transaction of $12,000.00. Following the sale, the chief executive officer now owns 15,202,352 shares in the company, valued at $76,011,760. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

David Zaccardelli also recently made the following trade(s):

• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The stock was sold at an average price of $4.39, for a total transaction of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $1,076,533.92.

Verona Pharma Stock Down 5.3 %

Shares of VRNA opened at $36.93 on Thursday. Verona Pharma plc has a 52 week low of $11.39 and a 52 week high of $40.13. The company has a debt-to-equity ratio of 0.93, a quick ratio of 12.88 and a current ratio of 13.03. The stock has a market capitalization of $2.97 billion, a price-to-earnings ratio of -19.23 and a beta of 0.42. The stock has a fifty day moving average of $32.23 and a 200-day moving average of $23.30.

Verona Pharma (NASDAQ:VRNA) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). The firm had revenue of $5.62 million for the quarter, compared to the consensus estimate of $2.31 million. During the same quarter in the prior year, the company posted ($0.18) earnings per share. As a group, sell-side analysts anticipate that Verona Pharma plc will post -2.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Wells Fargo & Company raised their price target on shares of Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Canaccord Genuity Group lifted their price objective on Verona Pharma from $37.00 to $44.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. HC Wainwright raised their price target on Verona Pharma from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, Truist Financial boosted their target price on shares of Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $43.83.

Institutional Investors Weigh In On Verona Pharma

Hedge funds have recently added to or reduced their stakes in the business. CWM LLC bought a new stake in shares of Verona Pharma during the second quarter valued at approximately $29,000. EMC Capital Management purchased a new stake in Verona Pharma in the 2nd quarter valued at about $38,000. GAMMA Investing LLC raised its stake in shares of Verona Pharma by 70.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock worth $38,000 after purchasing an additional 553 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Verona Pharma by 25.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock valued at $75,000 after purchasing an additional 529 shares during the last quarter. Finally, Legato Capital Management LLC purchased a new stake in Verona Pharma during the second quarter valued at about $154,000. 85.88% of the stock is currently owned by institutional investors.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.